The most effective non-surgical therapeutic combination in the treatment of Peyronie's disease proposed by international experts in Peyronie's disease at a Beaulieu Clinical Center of Excellence!
The effectiveness of Xiaflex™ has been demonstrated by numerous clinical studies in Peyronie's disease and its association with RestoreX™ further improves the benefits of injecting Collagenase Clostridium Histolyticum into the fibrosis plaque.
This combination was the subject of a prospective and randomized clinical study published by M. Alom et al in the Journal of Sexual Medecine5a https://pubmed.ncbi.nlm.nih.gov/30956106.
This study measures the efficacy of RestoreX™ combined with Collagenase Clostridium Histolyticum (CCH) versus 2 groups, CCH alone and CCH combined with other traction therapy devices:
-> Group 1 → CCH alone: curvature = +20.3° (+31%) / length = -0.7 cm (-4%)
-> Group 2 → CCH + other traction therapies: curvature = +19.2° (+30%) / length = -0.4 cm (-2%)
-> Group 3 → CCH + RestoreX™: curvature = +33.8° (+49%) / length = +1.9 cm (+17%)
Injecting Xiaflex™* into the fibrotic plaque is a surgical technique requiring perfect knowledge of anatomical landmarks and very precise injection into the tunica albuginea. Only experts with extensive experience in Peyronie's disease are qualified to perform these injections.
The urologists of the MHISC group offer this care by conducting an initial video consultation and establishing a tailored, personalized treatment program based on multiple injections and training in traction therapy.
Depending on the analysis of your case, a surgical alternative may be proposed -> Peyronie's disease
Carlo BETTOCCHI, MD
Grégoire MAYOR, MD
The MHISC center of excellence (Mens Health International Surgical Center) is based in Geneva, at the Clinique Générale - Beaulieu
This facility discreetly welcomes international customers and provides all the additional services likely to make your care easier and more pleasant.
Contact us for video-consultation appointments: enquiries@mhisc.ch
